Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.
Zhang H, Xu N, Xu Y, Qin P, Dai R, Xu B, Wang S, Ding L, Fu J, Zhang S, Hua Q, Liao Y, Yang J, Hu X, Jiang J, Lv H.
Zhang H, et al. Among authors: dai r.
Nat Commun. 2023 Aug 8;14(1):4757. doi: 10.1038/s41467-023-40489-2.
Nat Commun. 2023.
PMID: 37553338
Free PMC article.
Clinical Trial.